ICON Awarded Clinical Research Team of the Year and Best in Health Economics and Outcomes Research
2019年5月13日 - 8:00PM
ビジネスワイヤ(英語)
ICON Wins Multiple Awards at the 2019
Clinical and Research Excellence Awards
ICON plc, (NASDAQ: ICLR) a global provider of drug and
device development and commercialisation services to
pharmaceutical, biotechnology, medical device industries, today
announced that it has been awarded the Clinical Research Team of
the Year (with Eli Lilly and Company), for the second consecutive
year, and Best in Health Economics and Outcomes Research (with
Bristol-Myers Squibb and LATITUDE, powered by AXON). The awards
were presented at the annual Clinical and Research Excellence
(CARE) Awards, which took place in Boston, Mass. on 2 May 2019.
The awards indicated are ICON’s third win for Clinical Research
Team of the Year since the inaugural CARE Awards in 2016, and first
win in the Best Health Economics and Outcomes Research category.
These awards honoured the achievements of the teams and are a
testament to the company’s overall strength of partnership in the
industry.
ICON and Eli Lilly and Company won the award for the successful
execution of a full-service Cardiovascular Outcomes Trial (CVOT),
in which they were able to achieve exceptional patient retention
despite early challenges. The team’s proactive management and
flawless execution, resulted in the data disclosure of the first
Type 2 Diabetes Mellitus medicine to demonstrate superiority in the
reduction of major adverse cardiac events (MACE) in a clinical
trial that included a majority of participants who did not have
established cardiovascular (CV) disease.
The ICON team, together with Bristol-Meyers Squibb and LATITUDE
(powered by AXON), were able to execute a long-term oncological
trial comparing treatment regimens with three different
therapeutics, over five years, in multiple geographies. ICON
demonstrated significant expertise through the application of a
Real World Evidence approach, which met the needs of the sponsor,
the clinician, the patient and the payer.
Commenting on the award, ICON’s Chief Executive Officer, Steve
Cutler, said: “We are delighted that our comprehensive approach to
partnership as well as the expertise of our clinical research teams
has received industry recognition. One of our key priorities is
helping our clients expedite drug development to improve outcomes
and this has been successfully achieved through the diligence and
work ethic of the joint partnership teams.”
About ICON plc ICON plc is a global provider of drug and
device development and commercialisation services to
pharmaceutical, biotechnology, medical device and government and
public health organisations. The company specialises in the
strategic development, management and analysis of programs that
support clinical development - from compound selection to Phase
I-IV clinical studies. With headquarters in Dublin, Ireland, ICON
employed approximately 13,920 employees in 90 locations in 37
countries as at March 31, 2019.
Further information is available at www.iconplc.com.
ICON/ICLR-G
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190513005026/en/
ICON Media ContactLucinda Sandon-AllumWeber Shandwick+44
(0)20 7067 0548lsandon-allum@webershandwick.com
ICON (NASDAQ:ICLR)
過去 株価チャート
から 6 2024 まで 7 2024
ICON (NASDAQ:ICLR)
過去 株価チャート
から 7 2023 まで 7 2024